About Haima Therapeutics

Company Mission

Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for the treatment of bleeding and a variety of blood-related diseases. Haima’s initial focus is on platelet-inspired therapies to mitigate active bleeding and bleeding risks after traumatic injury, surgery, thrombocytopenia, and rare bleeding disorders. Haima’s lead technology, called SynthoPlate, is a novel, fully-synthetic hemostatic agent that mitigates bleeding by acting at the site of injury and amplifying your body’s natural clotting mechanisms.